Evidence map›Paper›PMID 28344825›Full record

ArticleFuture science OA2017

Identification of Filamin-A and -B as potential biomarkers for prostate cancer.

Niven R Narain, Anne R Diers, Arleide Lee, Socheata Lao, Joyce Y Chan, Sally Schofield, Joe Andreazi, Rakibou Ouro-Djobo, Joaquin J Jimenez, Tracey Friss and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Biological roles of filamin a in prostate cancer cells.International braz j urol : official journal of the Brazilian Society of Urology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Niven R NarainBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.
Anne R DiersBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.
Arleide LeeBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.
Socheata LaoBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.
Joyce Y ChanBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.
Sally SchofieldBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.
Joe AndreaziBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.
Rakibou Ouro-DjoboBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.
Joaquin J JimenezDepartment of Dermatology, University of Miami Miller School of Medicine, Miami, FL, USA 33136; Department of Dermatology, University of Miami Miller School of Medicine, Miami, FL, USA 33136.
Tracey FrissBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.
Nikunj TannaBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.
Aditee DalviBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.
Sihe WangDepartment of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA 44195; Department of Chemistry, Cleveland State University, Cleveland, OH, USA 44115; Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA 44195; Department of Chemistry, Cleveland State University, Cleveland, OH, USA 44115.
Dustin BunchDepartment of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA 44195; Department of Chemistry, Cleveland State University, Cleveland, OH, USA 44115; Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA 44195; Department of Chemistry, Cleveland State University, Cleveland, OH, USA 44115.
Yezhou SunBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.
Wenfang WuBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.
Khampaseuth ThapaBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.
Stephane GestaBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.
Leonardo O RodriguesBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.
Viatcheslav R AkmaevBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.
Vivek K VishnudasBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.
Rangaprasad SarangarajanBerg, LLC, Framingham, MA, USA; Berg, LLC, Framingham, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimA novel strategy for prostate cancer (PrCa) biomarker discovery is described. MATERIALS &

methods

resultsFilamin-B (FLNB) and Keratin-19 were identified as biomarkers. Filamin-A (FLNA) was found to be causally linked to FLNB. Characterization of the biomarkers in a panel of cells revealed differential mRNA expression and regulation. Moreover, FLNA and FLNB were detected in the conditioned media of cells. Last, in patients without PrCa, FLNA and FLNB blood levels were positively correlated, while in patients with adenocarcinoma the relationship is dysregulated.

conclusionThese data support the strategy and the potential use of the biomarkers for PrCa.

Indexed as

Bayesian network learningbiomarkersFLNAFLNBKRT19prostate cancer

Identifiers

PMID28344825
PMCPMC5351499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.